Bavarian Nordic A/S (BVNRY)
| Market Cap | 2.51B -11.4% |
| Revenue (ttm) | 968.53M -1.8% |
| Net Income | 235.73M +8.4% |
| EPS | 2.97 +8.1% |
| Shares Out | n/a |
| PE Ratio | 10.66 |
| Forward PE | 18.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170 |
| Open | 11.04 |
| Previous Close | 11.16 |
| Day's Range | 11.04 - 11.04 |
| 52-Week Range | 8.67 - 13.00 |
| Beta | 0.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses... [Read more]
Financial Performance
In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.
Financial numbers in DKK Financial StatementsNews
Bavarian Nordic Earnings Call Transcript: Q2 2026
H1 2026 revenue exceeded DKK 3 billion with 35% EBITDA margin, driven by strong Travel Health and Public Preparedness growth. Full-year guidance was upgraded to DKK 5.7 billion revenue and 30% EBITDA margin, with a new DKK 750 million share buyback announced.
Bavarian Nordic Quarterly report: Q2 2026
Bavarian Nordic has published its Q2 2026 quarterly earnings report on August 21, 2026.
Bavarian Nordic Slides: Q2 2026
Bavarian Nordic has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 21, 2026.
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
Global warming is increasing the spread of tick-borne encephalitis and chikungunya viruses, the chief executive of vaccine maker Bavarian Nordic said on Friday.
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares fo...
Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chi...
Bavarian Nordic Secures Additional Government Contract for the Supply of Smallpox/Mpox Vaccine
COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its MVA-BN® smallpox/mpox vaccine to an und...
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manage...
Bavarian Nordic Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue of DKK 1,058 million and a 16% EBITDA margin, with strong travel health growth and upgraded full-year guidance following a new BARDA contract. Travel health and public preparedness segments both contributed, and cash position remains robust.
Bavarian Nordic Quarterly report: Q1 2026
Bavarian Nordic has published its Q1 2026 quarterly earnings report on May 13, 2026.
Bavarian Nordic Slides: Q1 2026
Bavarian Nordic has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026.
Denmark's Bavarian Nordic raises 2026 forecast
Denmark's Bavarian Nordic on Monday raised its revenue guidance for 2026 to 5.5 billion - 5.7 billion Danish crowns ($866.93 million-$898.46 million).
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on March 12, 2026, has now been completed, reaching an ...
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results
Bavarian Nordic Receives Swissmedic Approval for Chikungunya Vaccine
COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for act...
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on
Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.
The first severe case of the virus has been detected in New York.
Bavarian Nordic Earnings Call Transcript: Q4 2025
Revenue reached DKK 6.2 billion in 2025, with strong growth in travel health and public preparedness, and a 28% EBITDA margin. 2026 guidance anticipates DKK 5–5.2 billion revenue and 25% EBITDA margin, with continued expansion in travel health and new agreements for chikungunya vaccine.
Bavarian Nordic Annual report: Q4 2025
Bavarian Nordic has published its Q4 2025 annual report on March 12, 2026.
Bavarian Nordic Slides: Q4 2025
Bavarian Nordic has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
Bavarian Nordic Publishes Annual Report 2025
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced ...
Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement
COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manu...
Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada
COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company's mpox an...